Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial

INTRODUCTION: As most patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) develop progressive disease after treatment with osimertinib, it is important to develop more effective treatment options. Afatinib has been shown to be more effective in in vitro st...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thorac Cancer
Autors principals: Kobayashi, Nobuaki, Hashimoto, Hisashi, Kamimaki, Chisato, Nagasawa, Ryo, Tanaka, Katsushi, Kubo, Sousuke, Katakura, Seigo, Chen, Hao, Hirama, Nobuyuki, Ushio, Ryota, Aoki, Ayako, Nakashima, Kentaro, Teranishi, Shuhei, Manabe, Saki, Watanabe, Hiroki, Horita, Nobuyuki, Watanabe, Keisuke, Hara, Yu, Yamamoto, Masaki, Kudo, Makoto, Piao, Hongmei, Kaneko, Takeshi
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons Australia, Ltd 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7396380/
https://ncbi.nlm.nih.gov/pubmed/32495514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13503
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars